Stockscreener 앱 받기
1.47
4.55%
-0.07
시간 외 거래:
1.47
전일 마감가:
$1.54
열려 있는:
$1.52
하루 거래량:
1.50M
Relative Volume:
0.78
시가총액:
$169.53M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.8909
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
-10.09%
1개월 성능:
+54.74%
6개월 성능:
+32.43%
1년 성능:
-54.35%
1일 변동 폭
$1.445
$1.53
1주일 범위
$1.30
$1.65
52주 변동 폭
$0.6611
$3.50
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.47 | 177.61M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Why Fate Therapeutics Inc. stock remains a top recommendationGDP Growth & Technical Entry and Exit Alerts - newser.com
How Fate Therapeutics Inc. stock benefits from global expansionStop Loss & Short-Term High Return Strategies - newser.com
Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
Is Fate Therapeutics Inc a good long term investmentInstitutional Holding Changes & Secret Picks Wall Street Isn’t Talking About - earlytimes.in
Using fundamentals and technicals on Fate Therapeutics Inc.Earnings Beat & Daily Market Momentum Tracking - newser.com
Is Fate Therapeutics Inc. stock reversal real or fakeMarket Movement Recap & Step-by-Step Trade Execution Guides - newser.com
Is Fate Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Published on: 2025-10-14 21:30:26 - newser.com
FATE appoints Kamal Adawi CFO as board reduces from 10 to 8 - Stock Titan
Fate Therapeutics, Inc. Appoints Kamal Adawi as Chief Financial Officer, Effective October 20, 2025 - MarketScreener
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer - GlobeNewswire
375,000-option grant leads Fate Therapeutics' appointment of Kamal Adawi as CFO, effective Oct 20, 2025 - Stock Titan
Automated trading signals detected on Fate Therapeutics Inc.Trade Exit Summary & Reliable Price Breakout Alerts - newser.com
Advanced analytics toolkit walkthrough for Fate Therapeutics Inc.Options Play & Community Driven Trade Alerts - newser.com
Published on: 2025-10-13 07:01:23 - newser.com
What technical signals suggest for Fate Therapeutics Inc. stockJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
What’s next for Fate Therapeutics Inc. stock priceWeekly Earnings Recap & High Win Rate Trade Alerts - newser.com
Risk vs reward if holding onto Fate Therapeutics Inc.July 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Historical volatility pattern of Fate Therapeutics Inc. visualizedEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Real time social sentiment graph for Fate Therapeutics Inc.Trade Volume Report & Verified Entry Point Signals - newser.com
Fate Therapeutics (NASDAQ:FATE) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Fate Therapeutics, Inc. $FATE Stock Holdings Lessened by Public Employees Retirement System of Ohio - Defense World
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Is Fate Therapeutics Inc. stock in correction or buying zoneJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Chart based analysis of Fate Therapeutics Inc. trendsMarket Activity Report & Real-Time Market Trend Scan - newser.com
Fate Therapeutics Inc. stock daily chart insightsPortfolio Performance Report & Weekly Breakout Stock Alerts - newser.com
What analysts say about Fate Therapeutics Inc stockPrice Gap Trading Strategies & Big Returns, Small Investment – Learn How - earlytimes.in
Detecting price anomalies in Fate Therapeutics Inc. with AI2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Is Fate Therapeutics Inc. stock trading at a premium valuationFed Meeting & Real-Time Buy Signal Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners may be pleased with recent gains after 62% loss over the past year - Yahoo Finance
Fate Therapeutics Reports New Employee Inducement Awards under Nasdaq Listing Rule 5635(4) - MarketScreener
Should you hold or exit Fate Therapeutics Inc. now2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
Top chart patterns to watch in Fate Therapeutics Inc.July 2025 Price Swings & High Return Trade Guides - newser.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics reports new employee inducement awards under Nasdaq listing rule - MarketScreener
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 62% over the previous year - simplywall.st
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.50%
자본화:
|
볼륨(24시간):